KYMERA THERAPEUTICS, INC. Revenue
KYMERA THERAPEUTICS, INC. (KYMR) reported Revenue of $65.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-05
- KYMERA THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $65.00M, a 466.40% increase year-over-year.
- KYMERA THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $34.37M, a 55.50% increase year-over-year.
- KYMERA THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $2.87M, a 61.18% decline year-over-year.
- KYMERA THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $2.76M, a 26.12% decline year-over-year.
- KYMERA THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $39.21M, a 16.70% decline from fiscal 2024.
- KYMERA THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $47.07M, a 40.11% decline from fiscal 2023.
- KYMERA THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $78.59M, a 67.84% increase from fiscal 2022.
- KYMERA THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $46.83M, a 35.71% decline from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $65.00M 10-Q · filed 2026-08-05 | $99.36M 10-Q · filed 2026-08-05 | $102.23M derived: sum of 3 quarters · filed 2026-08-05 | $105.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $34.37M 10-Q · filed 2026-04-30 | $37.23M derived: sum of 2 quarters · filed 2026-04-30 | $40.00M derived: sum of 3 quarters · filed 2026-04-30 | $51.48M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $2.87M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $5.63M derived: sum of 2 quarters · filed 2026-02-26 | $17.11M derived: sum of 3 quarters · filed 2026-08-05 | $39.21M 10-K · filed 2026-02-26 |
| 2025-09-30 | $2.76M 10-Q · filed 2025-11-04 | $14.24M derived: sum of 2 quarters · filed 2026-08-05 | $36.34M 10-Q · filed 2025-11-04 | $43.73M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $11.48M 10-Q · filed 2026-08-05 | $33.58M 10-Q · filed 2026-08-05 | $40.97M derived: sum of 3 quarters · filed 2026-08-05 | $44.71M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $22.10M 10-Q · filed 2026-04-30 | $29.49M derived: sum of 2 quarters · filed 2026-04-30 | $33.23M derived: sum of 3 quarters · filed 2026-04-30 | $58.88M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $7.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $11.13M derived: sum of 2 quarters · filed 2026-02-26 | $36.78M derived: sum of 3 quarters · filed 2026-02-26 | $47.07M 10-K · filed 2026-02-26 |
| 2024-09-30 | $3.74M 10-Q · filed 2025-11-04 | $29.39M derived: sum of 2 quarters · filed 2025-11-04 | $39.68M 10-Q · filed 2025-11-04 | $87.56M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $25.65M 10-Q · filed 2025-08-11 | $35.94M 10-Q · filed 2025-08-11 | $83.82M derived: sum of 3 quarters · filed 2026-02-26 | $88.55M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $10.29M 10-Q · filed 2025-05-09 | $58.17M derived: sum of 2 quarters · filed 2026-02-26 | $62.90M derived: sum of 3 quarters · filed 2026-02-26 | $79.41M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $47.88M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $52.61M derived: sum of 2 quarters · filed 2026-02-26 | $69.13M derived: sum of 3 quarters · filed 2026-02-26 | $78.59M 10-K · filed 2026-02-26 |
| 2023-09-30 | $4.73M 10-Q · filed 2024-10-31 | $21.24M derived: sum of 2 quarters · filed 2024-10-31 | $30.71M 10-Q · filed 2024-10-31 | $46.85M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $16.51M 10-Q · filed 2024-08-07 | $25.98M 10-Q · filed 2024-08-07 | $42.12M derived: sum of 3 quarters · filed 2025-02-27 | $51.67M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $9.47M 10-Q · filed 2024-05-02 | $25.61M derived: sum of 2 quarters · filed 2025-02-27 | $35.16M derived: sum of 3 quarters · filed 2025-02-27 | $46.67M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $16.14M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $25.69M derived: sum of 2 quarters · filed 2025-02-27 | $37.20M derived: sum of 3 quarters · filed 2025-02-27 | $46.83M 10-K · filed 2025-02-27 |
| 2022-09-30 | $9.55M 10-Q · filed 2023-11-02 | $21.07M derived: sum of 2 quarters · filed 2023-11-02 | $30.69M 10-Q · filed 2023-11-02 | $45.96M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $11.51M 10-Q · filed 2023-08-03 | $21.14M 10-Q · filed 2023-08-03 | $36.41M derived: sum of 3 quarters · filed 2024-02-22 | $56.75M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $9.62M 10-Q · filed 2023-05-04 | $24.90M derived: sum of 2 quarters · filed 2024-02-22 | $45.23M derived: sum of 3 quarters · filed 2024-02-22 | $63.75M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $15.28M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $35.61M derived: sum of 2 quarters · filed 2024-02-22 | $54.13M derived: sum of 3 quarters · filed 2024-02-22 | $72.83M 10-K · filed 2024-02-22 |
| 2021-09-30 | $20.34M 10-Q · filed 2022-11-03 | $38.85M derived: sum of 2 quarters · filed 2022-11-03 | $57.56M 10-Q · filed 2022-11-03 | $70.34M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $18.52M 10-Q · filed 2022-08-09 | $37.22M 10-Q · filed 2022-08-09 | $50.01M derived: sum of 3 quarters · filed 2023-02-23 | $64.54M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $18.70M 10-Q · filed 2022-05-03 | $31.49M derived: sum of 2 quarters · filed 2023-02-23 | $46.02M derived: sum of 3 quarters · filed 2023-02-23 | $49.31M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $12.79M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $27.32M derived: sum of 2 quarters · filed 2023-02-23 | $30.61M derived: sum of 3 quarters · filed 2023-02-23 | $34.03M 10-K · filed 2023-02-23 |
| 2020-09-30 | $14.53M 10-Q · filed 2021-11-10 | $17.82M derived: sum of 2 quarters · filed 2021-11-10 | $21.25M 10-Q · filed 2021-11-10 | $23.08M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $3.29M 10-Q · filed 2021-08-06 | $6.72M 10-Q · filed 2021-08-06 | $8.55M derived: sum of 3 quarters · filed 2022-02-24 | $9.50M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $3.43M 10-Q · filed 2021-05-06 | $5.26M derived: sum of 2 quarters · filed 2022-02-24 | $6.21M derived: sum of 3 quarters · filed 2022-02-24 | |
| 2019-12-31 | $1.83M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $2.78M derived: sum of 2 quarters · filed 2022-02-24 | $2.93M 10-K · filed 2022-02-24 | |
| 2019-09-30 | $950.00K 10-Q · filed 2020-11-05 | $1.10M 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |